Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer

Journal of Clinical Oncology

Volumn 22, Issue 24, 2004, Pages 4958-4965

  Diéras, Véronique ^a   Fumoleau, Pierre ^a   Romieu, Gilles ^a   Tubiana Hulin, Michèle ^a   Namer, Moïse ^a   Mauriac, Louis ^a   Guastalla, Jean Paul ^a   Pujade Lauraine, Eric ^a   Kerbrat, Pierre ^a   Maillart, Philippe ^a   Pénault Llorca, Frédérique ^a   Buyse, Marc ^a   Pouillart, Pierre ^a  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HORMONE RECEPTOR; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATHOLOGIST; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT RESPONSE; ADENOCARCINOMA; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TREATMENT OUTCOME;

EID: 16644384267     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.122     Document Type: Article

References (29)

1. Bonadonna G, Valagussa P, Zucali R, et al: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45:227-243, 1995
2. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
3. Schwartz G, Birchansky C, Komarnicky L, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994
4. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
5. Ragaz J, Knowling M, Jones G, et al: Comparability of preoperative (neoadjuvant) (pre) and (post) (TH) for locally advanced breast cancer (LABC). Proc Am Assoc Cancer Res 28:197, 1987
6. Fisher B, Brown A, Mamounas E, et al: Effect of chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
7. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
8. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
9. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
10. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
11. Abrams JC, Vena DH, Boltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
12. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411, 1999
13. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
14. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel (TaxoD/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994
15. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
16. Chevallier B, Roche H, Olivier JP, et al: Inflammatory breast cancer. Am J Clin Oncol 16:223-228, 1993
17. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-304, 1995
18. Fleming TR: One-sampling multiple testing procedure for the phase II clinical trials. Biometrics 38:143-151, 1982
19. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
20. Morrell LE, Lee YJ, Hurley J, et al: A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 82:503-511, 1998
21. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
22. Bear HD, Anderson S, Brown A, et al: The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
23. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
24. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
25. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2:347-354, 1991
26. Shannon C, Smith I: Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45:77-90, 2003
27. Teixeira MR, Pandis-N, Bardi G, et al: Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 56:855-859, 1996
28. Kuukasjärvi T, Karhu R, Tanner M, et al: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597-1604, 1997
29. Fumoleau P, Tubiana-Hulin M, Romieu G, et al: A randomized phase II study of 4 or 6 cycles of Adriamycin/Taxol (paclitaxel) as neoadjuvant treatment of breast cancer. Breast Cancer Res 69:209-325, 2001 (abstr)